PMC:7601109 / 5117-5322 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T49570","span":{"begin":162,"end":167},"obj":"http://purl.obolibrary.org/obo/CLO_0001195"}],"text":"d as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly u"}

{"project":"LitCovid-sentences","denotations":[{"id":"T32","span":{"begin":126,"end":169},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"d as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly u"}

{"project":"LitCovid-PubTator","denotations":[{"id":"112","span":{"begin":36,"end":46},"obj":"Chemical"},{"id":"113","span":{"begin":48,"end":54},"obj":"Chemical"},{"id":"114","span":{"begin":57,"end":66},"obj":"Chemical"},{"id":"115","span":{"begin":68,"end":75},"obj":"Chemical"},{"id":"116","span":{"begin":78,"end":89},"obj":"Chemical"},{"id":"117","span":{"begin":91,"end":99},"obj":"Chemical"}],"attributes":[{"id":"A112","pred":"tao:has_database_id","subj":"112","obj":"MESH:C000596367"},{"id":"A113","pred":"tao:has_database_id","subj":"113","obj":"MESH:C000596367"},{"id":"A115","pred":"tao:has_database_id","subj":"115","obj":"MESH:C547106"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"d as anti-sarcopenic agents such as bimagrumab (BYM338), enobasarm (GTx-024), trevogrumab (REGN1033), and sarconeos (BIO101). Most trials are in phase 1 or phase 2 [19]. In addition, outcomes of commonly u"}